(ALNY) Alnylam Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02043Q1076
ALNY EPS (Earnings per Share)
ALNY Revenue
ALNY: RNA Interference, Therapeutics, Amyloidosis, Porphyria, Hypercholesterolemia
Alnylam Pharmaceuticals is a biotechnology company that leverages RNA interference (RNAi) technology to develop and commercialize treatments for various diseases. The companys product portfolio includes approved therapies such as ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio, targeting conditions like hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.
The companys pipeline is robust, with multiple candidates in various stages of clinical development. Notable assets include vutrisiran, fitusiran, cemdisiran, and zilebesiran, which are being investigated for conditions such as transthyretin amyloidosis, hemophilia, myasthenia gravis, and hypertension. Alnylams partnerships with prominent pharmaceutical companies like Regeneron Pharmaceuticals, Roche Holding AG, and Sanofi S.A. underscore its commitment to advancing RNAi therapeutics.
From a technical analysis perspective, ALNYs stock has demonstrated a strong uptrend, with the last price at $306.09, above its 20-day, 50-day, and 200-day moving averages. The Average True Range (ATR) indicates moderate volatility, with a 3.51% daily price movement. Given the current technical setup, a potential price target could be $320-$330, based on the stocks momentum and the absence of significant resistance levels nearby.
Fundamentally, Alnylams market capitalization stands at approximately $37.8 billion, with a forward P/E ratio of 909.09, indicating high growth expectations. The companys return on equity (RoE) is negative, which is not uncommon for biotech firms with significant R&D investments. As the companys pipeline assets progress through clinical trials and potentially gain approval, the stocks valuation could be positively impacted. Assuming successful trial outcomes and subsequent commercialization, a potential long-term target for ALNY could be $400-$450, driven by the expected growth in revenue and earnings.
Combining technical and fundamental insights, a forecast for ALNY suggests potential short-term gains, driven by the stocks current momentum, and long-term growth, driven by the companys promising pipeline and partnerships. Investors should closely monitor clinical trial updates, regulatory decisions, and industry trends to adjust their investment strategies accordingly.
Additional Sources for ALNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ALNY Stock Overview
Market Cap in USD | 38,931m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2004-05-28 |
ALNY Stock Ratings
Growth Rating | 51.6 |
Fundamental | -11.1 |
Dividend Rating | 0.0 |
Rel. Strength | 116 |
Analysts | 4 of 5 |
Fair Price Momentum | 299.72 USD |
Fair Price DCF | - |
ALNY Dividends
Currently no dividends paidALNY Growth Ratios
Growth Correlation 3m | 71.8% |
Growth Correlation 12m | 18% |
Growth Correlation 5y | 68.6% |
CAGR 5y | 15.42% |
CAGR/Max DD 5y | 0.36 |
Sharpe Ratio 12m | -0.18 |
Alpha | 85.53 |
Beta | 1.019 |
Volatility | 40.38% |
Current Volume | 570.6k |
Average Volume 20d | 747.5k |
As of June 19, 2025, the stock is trading at USD 308.71 with a total of 570,558 shares traded.
Over the past week, the price has changed by +2.07%, over one month by +5.77%, over three months by +21.97% and over the past year by +96.26%.
Neither. Based on ValueRay´s Fundamental Analyses, Alnylam Pharmaceuticals is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.06 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALNY is around 299.72 USD . This means that ALNY is currently overvalued and has a potential downside of -2.91%.
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy ALNY.
- Strong Buy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- Strong Sell: 1
According to our own proprietary Forecast Model, ALNY Alnylam Pharmaceuticals will be worth about 345.4 in June 2026. The stock is currently trading at 308.71. This means that the stock has a potential upside of +11.89%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 320.6 | 3.9% |
Analysts Target Price | 320.6 | 3.9% |
ValueRay Target Price | 345.4 | 11.9% |